Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY

Newsfile June 19, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 19, 2023

Chinook Investor Alert

Newsfile June 18, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 17, 2023

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

GlobeNewswire June 17, 2023

ALERT: The M&A Class Action Firm Continues Investigating the Merger - PRTK, KDNY, BG, WTT

PR Newswire June 17, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY

PR Newswire June 15, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 15, 2023

Chinook Investor Alert

Newsfile June 14, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 14, 2023

CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY

Business Wire June 13, 2023

Chinook Shareholder Action Reminder

Newsfile June 13, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY

Newsfile June 13, 2023

Moore Kuehn Encourages KDNY, USX, CIR, and HMPT Investors to Contact Law Firm

PR Newswire June 13, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 13, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chinook Therapeutics, Inc. Buyout

Newsfile June 12, 2023

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

GlobeNewswire June 12, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, PRTK, KDNY

PR Newswire June 12, 2023

Shareholder Alert: Ademi LLP investigates whether Chinook Therapeutics, Inc. has obtained a Fair Price in its transaction with Novartis

PR Newswire June 12, 2023

KDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to Shareholders

Business Wire June 12, 2023